N+1 Singer reissued their buy rating on shares of Midatech Pharma PLC (LON:MTPH) in a research note published on Friday. The brokerage currently has a GBX 283 ($3.69) price target on the stock.

Separately, Panmure Gordon restated a buy rating and set a GBX 380 ($4.96) target price on shares of Midatech Pharma PLC in a research note on Friday.

Shares of Midatech Pharma PLC (LON:MTPH) traded up 2.01% during midday trading on Friday, hitting GBX 127.00. 3,522 shares of the stock were exchanged. The company’s market capitalization is GBX 42.60 million. The firm has a 50-day moving average of GBX 145.06 and a 200-day moving average of GBX 141.57. Midatech Pharma PLC has a 1-year low of GBX 100.51 and a 1-year high of GBX 285.00.

About Midatech Pharma PLC

Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company’s segments include Pipeline Research and Development, and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms.

Receive News & Stock Ratings for Midatech Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma PLC and related stocks with our FREE daily email newsletter.